Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 2/3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Warts 1Papillomavirus Infections 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Dexamethasone 12Gemcitabine 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Docetaxel 9venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7Methotrexate 6130-nm albumin-bound paclitaxel 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Human Papillomavirus Recombinant Vaccine nonavalent × Clear all
NCT05625633 2024-04-05

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Western Institute for Veterans Research

Phase 2/3 Recruiting
120 enrolled

Warts, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡